Loading
NAD+ falls with age, and swallowing a precursor raises it in the blood. That much is established. Whether raising it does anything for a person who has had cancer is not. The one B3 compound with a real cancer result is plain nicotinamide, for preventing skin cancers in people who keep getting them, which is a different claim entirely.
Nicotinamide riboside and nicotinamide mononucleotide are precursors of nicotinamide adenine dinucleotide. They raise blood NAD+ reliably: in NR-SAFE, a randomised double-blind trial of 20 people with Parkinson's disease given 1,500 mg twice daily for four weeks, there were no moderate or severe adverse events and blood NAD+ rose up to fivefold. That is a safety and pharmacokinetic result, not an efficacy one, and the trial was in Parkinson's disease, not cancer.
The compound in this family with a hard clinical result is nicotinamide itself. In the ONTRAC trial, 386 people who had had at least two non-melanoma skin cancers in the previous five years took nicotinamide 500 mg twice daily or placebo for 12 months. New non-melanoma skin cancers were 23 per cent lower (95% CI 4 to 38, P = 0.02), with no noteworthy difference in adverse events and no benefit after the drug was stopped. That is a chemoprevention result in a high-risk skin group; it is not evidence that nicotinamide, or any NAD+ precursor, slows ageing or repairs anything after chemotherapy.
There is no randomised trial of an NAD+ precursor in cancer survivors for recovery, fatigue or biological age. There is also an unresolved laboratory question about whether raising NAD+ favours tumour cells, which NAD-dependent repair enzymes also use; no human data settle it either way. The honest summary is that these are well tolerated, do what they say to a blood level, and have never been shown to do anything a survivor would notice.
NAD+ is the cofactor for sirtuins, PARPs and CD38 and falls with age in several tissues. Oral precursors enter the salvage pathway and raise NAD+ in blood and some tissues; the hypothesis is that restoring the cofactor restores sirtuin-dependent repair and mitochondrial function.
Query for this technology: (TITLE:"nicotinamide riboside" OR ABSTRACT:"nicotinamide riboside" OR TITLE:"nicotinamide mononucleotide" OR ABSTRACT:"nicotinamide mononucleotide" OR TITLE:"NAD+ precursor" OR ABSTRACT:"NAD+ precursor"). Results are unfiltered search hits about NAD+ precursors taken by mouth, not a curated reading list.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.
Shares What actually works after treatment, Late effects and survivorship toxicity, Survivorship care and late-effects surveillance, Survivorship and late effects are neglected and the tags rejuvenation, survivorship.